To compare the prognosis and adverse reactions of unresectable hepatocellular carcinoma receiving stereotactic radiotherapy combined with hepatic arterial chemoembolization and conversion hepatectomy

Inclusion Criteria:

• Unresectable HCC patients were diagnosed by a surgeon and/or radiologist and oncologist according to the international guidelines for the management of HCC or by pathology
• Patients who received SBRT plus TACE have tumor regression, and surgical experts assess that R0 resection could be achieved
• CP-A or B classification;
• Eastern Cooperative Oncology Group (ECOG) score 0-1;
• Platelet count≥50 × 109/L, white blood count≥1.5 × 109/L;
• ICG R15≤10%;
• Normal effective liver volume >30%;
• patients infected with hepatitis B virus who are treated with adefovir or entecavir; patients infected with hepatitis C virus whose HCV DNA are negative.

Exclusion Criteria:

-the patients receive other treatments (such as targeted treatment, immune checkpoint inhibitors,etc) after CK-SBRT plus TACE.

Unresectable HCC patients meet surgical criteria after CK-SBRT plus TACE.